Overview

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).
Phase:
Phase 3
Details
Lead Sponsor:
Avanir Pharmaceuticals